Mitigating Ibrutinib‐Induced Ventricular Arrhythmia and Cardiac Dysfunction With Metformin
The study concludes that metformin effectively mitigates ibrutinib-induced cardiotoxicity, including ventricular arrhythmia and cardiac dysfunction, by enhancing AMPK and PI3K-AKT pathway activity. These findings suggest that metformin holds potential as a therapeutic strategy to protect against the adverse cardiac effects associated with ibrutinib treatment, offering a promising approach for improving the cardiovascular safety of patients undergoing therapy for B cell cancers.
Authors
- Qiankun Bao (ORCID: https://orcid.org/0000-0002-5221-2780)
- Pengsha Li
- Gary Tse (ORCID: https://orcid.org/0000-0001-5510-1253)
- Ming Yuan (ORCID: https://orcid.org/0000-0003-4940-8253)
- Daiqi Liu
- Zhiqiang Zhao (ORCID: https://orcid.org/0000-0002-2081-3581)
- Zandong Zhou
- Yue Zhang (ORCID: https://orcid.org/0000-0002-4515-8931)
- Xing Liu (ORCID: https://orcid.org/0000-0002-3034-5179)
- Ying Liu (ORCID: https://orcid.org/0000-0001-9385-992X)
- Pan Gao (ORCID: https://orcid.org/0009-0000-0504-190X)
- Meng Yuan (ORCID: https://orcid.org/0000-0003-0087-6152)
- Qingling Zhang (ORCID: https://orcid.org/0009-0008-3723-398X)
- Guangping Li (ORCID: https://orcid.org/0000-0001-6677-3661)
Institutions
- Medway School of Pharmacy (GB)
- Sir Run Run Shaw Hospital (CN)
- Second Hospital of Tianjin Medical University (CN)
- Kent and Medway Medical School
- Tianjin Medical University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Cancer Innovation
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1002/cai2.151
- Citations
- 6
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 2.63
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Tianjin City